USA flag logo/image

An Official Website of the United States Government

Releasable site-specific attachment of macromolecules to therapeutic peptides

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96058
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
DK088481
Solicitation Year:
N/A
Solicitation Topic Code:
NIDDK
Solicitation Number:
N/A
Small Business Information
ProLynx LLC
211 Belgrave Ave San Francisco, CA 94117-3851
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Releasable site-specific attachment of macromolecules to therapeutic peptides
Agency: HHS
Contract: 1R43DK088481-01
Award Amount: $143,958.00
 

Abstract:

DESCRIPTION (provided by applicant): Many potent and specific peptides suffer problems of short or sub-optimal duration. A possible solution to such problems involves conjugation to macromolecules such as polyethylene glycol (PEG) that are slowly eliminate d from the body, and thus prolongs the action of the attached peptide. For peptide therapeutics, it is usually essential that the unchanged drug be released from the macromolecule with timing appropriate to satisfy the need. Current approaches often use cl eavable linkers to attach the peptide to the macromolecule by a linker that cleaves because of the effect of an enzyme, or physiological environment. Although such approaches are often successful, they usually do not allow prediction or control of the rate of drug release and hence the duration of action. The objective of this project is a) to develop a novel platform technology that allows site-specific attachment of a macromolecule to peptides, and b) to develop technology for predictable, chemically-cont rolled release of such peptides. If successful, a) we will have developed general technology for controlled release of peptides from macromolecules that could be broadly applied, and set the stage for future applications of such technology to therapeutic p eptides. PUBLIC HEALTH RELEVANCE: We propose to develop a novel platform technology that allows site-specific attachment of macromolecules to peptides, and predictable, controlled release of the native peptides that will allow an increase in the dur ation of their action. If successful, we will have developed general technology for controlled release of therapeutic peptides from macromolecules that could be broadly applied to the area of therapeutic peptides.

Principal Investigator:

Gary W. Ashley

Business Contact:

Daniel V. Santi
Daniel.V.Santi@gmail.com
Small Business Information at Submission:

PROLYNX, LLC
211 BELGRAVE AVE SAN FRANCISCO, CA 94117

EIN/Tax ID: 127033399
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No